Elevation Oncology (ELEV) News Today

$3.61
0.00 (0.00%)
(As of 05/17/2024 ET)
Elevation Oncology (NASDAQ:ELEV) Now Covered by Stephens
Elevation Oncology, Inc. (NASDAQ:ELEV) Receives Average Rating of "Buy" from Analysts
Elevation Oncology, Inc. (NASDAQ:ELEV - Get Free Report) has been given a consensus recommendation of "Buy" by the six research firms that are currently covering the firm, Marketbeat Ratings reports. Six investment analysts have rated the stock with a buy rating. The average 12 month price objecti
Elevation Oncology (NASDAQ:ELEV) Coverage Initiated by Analysts at Stephens
Stephens initiated coverage on shares of Elevation Oncology in a research note on Tuesday. They issued an "overweight" rating and a $8.00 target price on the stock.
Elevation Oncology (NASDAQ:ELEV) Given "Outperform" Rating at Wedbush
Wedbush reissued an "outperform" rating and issued a $8.00 price target on shares of Elevation Oncology in a research note on Friday.
Clariane: First Quarter 2024 Revenue
Elevation Oncology, Inc. (NASDAQ:ELEV) Short Interest Up 8.2% in March
Elevation Oncology, Inc. (NASDAQ:ELEV - Get Free Report) was the recipient of a significant growth in short interest in the month of March. As of March 31st, there was short interest totalling 5,010,000 shares, a growth of 8.2% from the March 15th total of 4,630,000 shares. Currently, 12.6% of the shares of the company are sold short. Based on an average daily volume of 3,060,000 shares, the days-to-cover ratio is currently 1.6 days.
Elevation Oncology (NASDAQ:ELEV) Earns Buy Rating from HC Wainwright
HC Wainwright restated a "buy" rating and set a $6.00 price target on shares of Elevation Oncology in a research report on Tuesday.
Short Interest in Elevation Oncology, Inc. (NASDAQ:ELEV) Expands By 28.3%
Elevation Oncology, Inc. (NASDAQ:ELEV - Get Free Report) was the target of a significant growth in short interest in the month of March. As of March 15th, there was short interest totalling 4,630,000 shares, a growth of 28.3% from the February 29th total of 3,610,000 shares. Based on an average daily volume of 2,940,000 shares, the days-to-cover ratio is currently 1.6 days. Approximately 11.6% of the company's stock are short sold.
All Three of Our Analysts Agree
Elevation Oncology, Inc. to Post Q4 2025 Earnings of ($0.16) Per Share, HC Wainwright Forecasts (NASDAQ:ELEV)
Elevation Oncology, Inc. (NASDAQ:ELEV - Free Report) - Equities research analysts at HC Wainwright issued their Q4 2025 EPS estimates for shares of Elevation Oncology in a note issued to investors on Thursday, March 7th. HC Wainwright analyst S. Ramakanth forecasts that the company will post earn
Elevation Oncology (NASDAQ:ELEV) Stock Rating Reaffirmed by JMP Securities
JMP Securities reiterated a "market outperform" rating and set a $7.00 price target on shares of Elevation Oncology in a research report on Thursday.
Elevation Oncology, Inc. Q4 Loss decreases, beats estimates
Elevation Oncology, Inc. (NASDAQ:ELEV) Shares Sold by Armistice Capital LLC
Armistice Capital LLC lowered its stake in shares of Elevation Oncology, Inc. (NASDAQ:ELEV - Free Report) by 68.7% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 750,000 shares of the company's stock
Elevation Oncology, Inc. (NASDAQ:ELEV) Sees Large Growth in Short Interest
Elevation Oncology, Inc. (NASDAQ:ELEV - Get Free Report) was the target of a large increase in short interest in February. As of February 15th, there was short interest totalling 4,010,000 shares, an increase of 13.9% from the January 31st total of 3,520,000 shares. Based on an average daily trading volume, of 2,620,000 shares, the short-interest ratio is presently 1.5 days. Approximately 11.6% of the shares of the stock are short sold.
Elevation Oncology (NASDAQ:ELEV) Coverage Initiated by Analysts at JMP Securities
JMP Securities began coverage on shares of Elevation Oncology in a research report on Friday. They set an "outperform" rating and a $7.00 price objective on the stock.
3 Stock Winners That Are Up 400% or More in 2024
Get Elevation Oncology News Delivered to You Automatically

Sign up to receive the latest news and ratings for ELEV and its competitors with MarketBeat's FREE daily newsletter.

A once-in-a-century investment opportunity (Ad)

It's an under-the-radar stock reshaping a projected $109 billion industry - And, I believe, has far more potential than the AI stocks most investors are focused on in the days ahead.

To get its name and ticker symbol for free - just click here.

ELEV Media Mentions By Week

ELEV Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

ELEV
News Sentiment

0.47

0.50

Average
Medical
News Sentiment

ELEV News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

ELEV Articles
This Week

6

1

ELEV Articles
Average Week

Get Elevation Oncology News Delivered to You Automatically

Sign up to receive the latest news and ratings for ELEV and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools

This page (NASDAQ:ELEV) was last updated on 5/18/2024 by MarketBeat.com Staff

From Our Partners